Description

Urea, N-[4-(4-Methyl-1-piperazinyl)phenyl]-N'-[4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-, CF3COOH salt is a high-purity, non-nucleoside reverse transcriptase inhibitor (NNRTI) intermediate of significant pharmaceutical importance. This compound is a critical building block in the research and development of novel antiviral therapeutics, particularly for HIV treatment. It is essential for pharmaceutical R&D laboratories, process chemistry teams, and manufacturers specializing in active pharmaceutical ingredients (APIs) for antiviral drugs.

Application

• Pharmaceutical Intermediate: Key synthetic precursor in the production of non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
• Antiviral Drug Development: Core building block for research into next-generation HIV-1 and HIV-2 treatments.
• Process Chemistry & Scale-Up: Used in route scouting, optimization, and pilot-scale manufacturing of target APIs.
• Biochemical Research: Serves as a reference standard and tool compound for studying viral enzyme inhibition mechanisms.
• Contract Manufacturing (CMO): Supplied to contract development and manufacturing organizations (CDMOs) for cGMP production.
• Preclinical Studies: Utilized in the synthesis of compounds for pharmacological and toxicological profiling.

Basic Information

Item	Details
Product Name	Urea, N-[4-(4-Methyl-1-piperazinyl)phenyl]-N'-[4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-, CF3COOH salt
CAS No.	1144076-41-4
Molecular Formula	C₃₃H₃₇F₃N₁₀O₃ • C₂HF₃O₂
Molecular Weight	Contact for details
Synonyms	GDC-0850 Trifluoroacetate Salt; GDC0850 TFA Salt; (R)-GDC-0850 TFA; NNRTI Intermediate GDC-0850; 1-(4-(4-Methylpiperazin-1-yl)phenyl)-3-(4-(4-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)urea trifluoroacetate; GDC 0850 TFA; GDC0850 Intermediate; Bicyclic Pyrazolopyrimidine Urea Derivative TFA Salt
EINECS	Contact for details

Quality Control

This pharmaceutical intermediate is produced under strict quality management systems. Every batch undergoes comprehensive analytical characterization, including HPLC for purity and chiral purity, NMR and MS for structural confirmation, and tests for residual solvents and elemental impurities. A detailed Certificate of Analysis (COA) is provided with each shipment, ensuring traceability and compliance with ICH Q7 guidelines for API starting materials. Custom synthesis and specific purity grades (e.g., >98%, >99%) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as indicated on the label. This material is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccant or inert atmosphere packaging.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (MS)	Conforms to structure
Purity (HPLC)	≥ 97.0%
Chiral Purity (HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	< 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.